Summary
Published in Scientific Reports (2025), this study introduces a novel 3D biomimetic brain cancer microtissue (BCM) model that enables the study of tumor cell interactions with neurons, astrocytes, and microglia. By co-culturing rat cortical microtissues with glioma cell lines using 3D Petri Dish® micro-molds, researchers demonstrated that glioblastoma cell behavior in the BCM model is consistent with in vivo observations, creating a platform for high-throughput therapeutic screening.
A brain cancer microtissue model for studying tumor cell and neural cell interactions
Research Overview
Glioblastoma is an aggressive brain cancer whose interactions with normal cells of the central nervous system are difficult to reproduce in vitro — patient-derived organoids and standard cultures capture aspects of the tumor but not its neural context. This study introduced a biomimetic brain cancer microtissue built by co-culturing rat cortical microtissues with rat glioma cell lines.
The model allowed characterization of glioma cell motility, invasiveness, and interactions with neurons, astrocytes, and microglia, with tumor cell behavior consistent with in vivo observations. The platform is robust and versatile, positioned for high-throughput therapeutic screening and for studying primary glioma biology as well as other cancers that involve the brain.
Key Discoveries
- Novel brain cancer co-culture model — The BCM model was developed by co-culturing rat cortical microtissues with rat glioma cell lines, enabling study of tumor-neural cell interactions that are difficult to model with existing in vitro approaches.
- Glioma behavior matches in vivo — Characterization showed that GBM cell motility, invasiveness, and interactions with neurons, astrocytes, and microglia in the BCM model are consistent with behavior observed in living organisms.
- Multi-cell type interactions captured — The platform successfully models complex interactions between tumor cells and normal central nervous system cells including neurons, astrocytes, and microglia.
- Enables high-throughput drug screening — The BCM model provides a platform for future therapeutic screening against glioblastoma and potentially other brain tumors and cancers that metastasize to the brain.
